Clinical Data BridgeBio stands up to Pfizer in ATTR-CM as late-stage data hint at better survival BioSpaceIndirect comparisons between BridgeBio's Attruby and Pfizer's tafamidis products showed a numerical survival benefit with the biotech's drug.CardiovascularRead full story pharminent May 12, 2026 (Last updated: May 12, 2026) BioSpace Indirect comparisons between BridgeBio’s Attruby and Pfizer’s tafamidis products showed a numerical survival benefit with the biotech’s drug. Cardiovascular Read full story Post navigation Previous: FDA turns to old drugs to address new diseases, persistent medical needsNext: EU agrees plan to tackle essential medicine shortages Related Stories Clinical Data Novartis hit as Lp(a) drug fails cardio outcomes trial pharminent September 7, 2026 Clinical Data Major trial of Roche Alzheimer’s drug kicks off in Europe pharminent September 7, 2026 Clinical Data AbbVie’s T cell engager delivers survival benefit in Phase 3 multiple myeloma study pharminent September 4, 2026